ViRexx Medical Corp. Licensing Partner Presents OvaRex(R) MAb Phase II Trial Results at American Society of Clinical Oncology
08 Jun 2007
AntibodyImmunotherapyASCO
EDMONTON, ALBERTA--(MARKET WIRE)--Jun 8, 2007 -- ViRexx Medical Corp. (Toronto:VIR.TO - News) (AMEX:REX - News), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced the results from a Phase II trial of OvaRex® MAb conducted by ViRexx's licensing partner, Unither Pharmaceuticals, Inc. (Unither), a subsidiary of United Therapeutics Corporation. Patients with newly diagnosed advanced ovarian cancer were treated by surgery and then by front-line chemotherapy in combination with OvaRex® MAb. The results were presented at the American Society of Clinical Oncology (ASCO) annual meeting. The trial demonstrated that cellular and humoral (antibody) immune responses to OvaRex® MAb treatment were preserved and in fact enhanced when administered with front-line treatment.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.